●The health care sector has been one of the year’s strongest sectors
●Big pharma has been consistently bullish within health care
●MRK and others have held ground during recent broad-market pullback
If someone asked you what the top-performing US stock sector has been this year, what would you tell them?
That’s not as stupid as it sounds. Long-term investors may define “top” differently than short-term traders, and if you throw in things like “risk-adjusted” or “short opportunities,” you can go down a lot of rabbit holes.
Solely in terms of return, of course, technology still rules the roost this year, as evidenced by the Nasdaq 100’s (NDX) outperformance vs. its major US index peers, as well as the tech sector’s year-to-date edge within the S&P 500 (SPX):
1. Information technology +15%
2. Consumer discretionary +14%
3. Health care +14%
But that edge has blunted a bit in recent months. Check out the following list of the top-performing S&P sectors measured over the past one, three, and six months (as of yesterday):
Source: OptionsHouse (as of 3 p.m. ET, 10/8/18)
While tech made an appearance on the six-month ranking, and consumer discretionary didn’t appear at all, health care made the top three at all intervals. Translation: Tech has been coasting lately, while health care has continued to fight the good fight, just maybe a little below the radar.
True, health care has participated in the broad market’s recent retreat, but that may lead some bulls to look for opportunities to buy pullbacks in what has been a consistently strong sector. Those traders would have to decide which ones offer the best balance of reward and risk.
There are six industries in the S&P health care sector, and while all of them except one (health care technology) are up one the year, there’s been a fair amount of rotation among them. Life sciences tools & services, for example, is up around 22% so far in 2018, but it’s in the red for the past month and down more than 5% over the past five days.
Biotech tends to get a lot of the health care publicity, and there’s no doubt some of these stocks have made some impressive moves—down as well as up. Volatility is a double-edged sword. Which could lead health care bulls to another idea: Pharmaceuticals. Specifically, large-cap pharmaceuticals—aka “big pharma.”
Just as health care has mostly held its ground as the sector rotation winds have swirled around it, at the industry level big pharma has been consistently in the green this year—even over the past week, when both the SPX and the health care sector dropped around 2%. Pharma’s YTD return (around 12%) may only be a little more than half that of life sciences, but it’s also at the top of its sector over the past month and most recent quarter.
Merck (MRK), for instance, is up more than 33% since early April and has barely budged from its recent record high of $72.42, despite the recent SPX pullback. It posted strong first-half results,1 and its new blockbuster cancer drug, Keytruda, has been making solid progress through the regulatory process.2
Strong industry, strong sector—something that may interest traders as well as investors when stocks are pulling back. A return to the upside by the broad market may give health care and pharma stocks another opportunity to pad their 2018 resumes.
Today’s numbers (all times ET): NFIB Small Business Optimism Index (6:00 a.m.), Canada Housing Starts (8:15 a.m.).
1 Zacks Equity Research. 5 Reasons Why Investors Should Bet on Merck (MRK) Stock. 10/18/18.
2 BioSpace. Merck’s Keytruda Nabs Another Approval, This One Under FDA’s Real-Time Program. 8/21/18.